Stocks and Investing
Stocks and Investing
Fri, May 3, 2024
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
[ Fri, May 03rd 2024
] - WOPRAI
Derek Archila Maintained (ASND) at Buy with Increased Target to $262 on, May 3rd, 2024
Derek Archila of Wells Fargo, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $260 to $262 on, May 3rd, 2024.
Derek has made no other calls on ASND in the last 4 months.
There are 3 other peers that have a rating on ASND. Out of the 3 peers that are also analyzing ASND, 1 agrees with Derek's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Vikram Purohit of "Morgan Stanley" Maintained at Hold and Held Target at $116 on, Monday, April 22nd, 2024
These are the ratings of the 2 analyists that currently disagree with Derek
- Andreas Argyrides of "Wedbush" Maintained at Buy with Increased Target to $225 on, Thursday, February 8th, 2024
- David Lebowitz of "Citigroup" Maintained at Strong Buy with Increased Target to $182 on, Thursday, February 8th, 2024
Contributing Sources